Retatrutide 30 mg

Retatrutide for research: identity and specifications

Retatrutide (CAS 2381089-83-2) is a synthetic peptide that acts as a triple agonist of the GIP, GLP-1 and glucagon receptors, studied in laboratory research on metabolic receptor pharmacology. Supplied as a 30 mg vial, lyophilized powder, with no fillers, carriers or excipients, at ≥98% purity by HPLC, synthesized and purified under documented analytical controls.

Scientific background

Agonism across three G protein-coupled receptors of the incretin and glucagon families makes the compound a model of interest for comparative pharmacology. In assays using cells that express each receptor, researchers investigate binding affinity, relative potency and cyclic AMP (cAMP) generation, assessing how simultaneous activation of the three targets differs from activation of each one alone.

Preclinical literature describes the use of triple agonists in rodent models to study energy expenditure and glucose and lipid metabolism, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• GIP, GLP-1 and glucagon receptor agonism in cell-based assays
• Relative potency and cAMP signaling at each receptor
• Glucose and lipid metabolism in experimental rodent models
• Comparative pharmacology of dual and triple agonists

Technical specifications

Analytical quality and chain of custody

Every lot of retatrutide is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) can be requested before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the retatrutide supplied?

≥98% by HPLC, with analytical information for the material available on the certificate of analysis (COA).

Are retatrutide and the code LY3437943 the same compound?

Yes, LY3437943 is the development code used in the literature for retatrutide, the triple GIP, GLP-1 and glucagon receptor agonist.

How should the compound be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Is a certificate of analysis available?

Yes, the COA can be requested before purchase, with the purity and identity data for the material.

Who can purchase retatrutide?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA and the molecular structure search in the PubChem database.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.